Revance absorbs $8M for topical Botox
Aesthetic drug developer Revance Therapeutics has landed $8 million in venture debt financing from Leader Ventures and Horizon Technology Finance. The money will be used to push its lead compound, a topical form of botulinum toxin type A (popularly known as Botox), through clinical stage trials.
While the injected form of the chemical has gained notoriety in the media, in reality, only about 10 percent of the targeted market (about 25 million women) has used it…. Continue Reading
Life sciences briefing: Wednesday, Dec. 12, 2007
TODAY’S HEADLINES:
Topical Botox maker Revance gets $43M, option to be acquired by Medicis (release)
Reva Medical draws $42M for resorbable stents (release)
AccentCare raises $8M for senior home-care services (VentureWire, sub req’d)
Light Dimensions aims for $6M for light-based skin treatment (VW)
Carigent pulls in $2M for nanoparticle drugs (release)
Celtic Pharma shoots for $1.5B in two drug-investment funds (VW)
Topical Botox developer Revance gets $43M, option to be acquired by Medicis — Mountain View, Calif.-based Revance Therapeutics, a developer of… Continue Reading